<DOC>
	<DOCNO>NCT02601989</DOCNO>
	<brief_summary>The aim continue program PDE5 inhibition evaluate effect insulin resistance , include glucose metabolism subclinical inflammation , 6-week administration tadalafil T2D patient . The primary objective study effect tadalafil compare placebo insulin sensitivity euglycemic hyperinsulinemic clamp . This double-blind , placebo-controlled crossover study one study site . Twenty-five T2D patient recruit randomized per oral intake tadalafil 20 mg o.d . six week wash-out period eight week intake placebo another six week , vice versa . At end 6 week treatment period glucose clamp , subcutaneous needle biopsy well muscle subcutaneous microdialysis perform . Endothelial function test arginin stimulation insulin secretion test perform 3 week treatment arm .</brief_summary>
	<brief_title>Effects Insulin Resistance With Tadalafil Type 2 Diabetes - Double-blind , Placebo-controlled Crossover Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . T2D patient , previously diagnose fast 2hr OGTT plasma glucose level 2 . Age female : 5570 yr ( postmenopausal state define natural amenorrhea least 12 month ) ; Age male : 4070 yr 3 . BMI : 2740 kg/m2 4 . HbA1c &lt; 60 mmol/mol 5 . Type 2 diabetes duration &gt; 3 month &lt; 10 yrs 6 . Understand speak Swedish 1 . Diabetes treatment glitazones , GLP1 analogues DPPIV inhibitor 2 . Antihypertensive therapy betablockers , ACEinhibitors and/or angiotensinII receptor blocker 3 . Significant microvascular complication e.g . nephropathy ( GFR &lt; 60 ) , proliferative retinopathy symptomatic neuropathy e.g . postural hypotension 4 . Previous significant vascular disease include angina pectoris myocardial infarction , cerebral artery disease e.g . history transient ischemic attack peripheral artery disease palpable pulse 5 . Smoking &gt; 10 cig/day and/or smokeless tobacco &gt; one per 2 day 6 . Concurrent use nitrate NO donor , apparent risk may need medication 7 . Cardiac failure ( stage NYHA IIIV ) 8 . Uncontrolled hypertension &gt; 170/105 mm Hg 9 . Apparent ECGpathology indicate current previous myocardial ischemia ; 10 . Males erectile dysfunction 11 . Hemophilia history bruise hepatic failure ( &gt; 2fold increase upper limit normal value ASAT/ALAT ) 12 . Hypotension 13 . Treatment doxazosin 14 . Anything contact patient make doctor believe he/she uncompliant protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>